An artificially intelligent (AI) robot ‘scientist’ has assisted researchers at the University of...
- AI robot aids scientists in malaria discovery
- DBV and Aimmune poised to dominate peanut allergy market
- Comorbidities are a significant concern in people with Type 2 diabetes
- Through CRISPR gene editing we can change the nature of our species
- Can Liquidia’s LIQ861 offer a more convenient and effective treprostinil option for PAH patients?
DBV and Aimmune poised to dominate peanut allergy market
Last week, the top two contenders for first peanut allergy immunotherapy to market—DBV Technologies and Aimmune Therapeutics—presented to investors at the J.P. Morgan (JPM) Healthcare Conference in San Francisco.
Malvern Panalytical Hosts Webinar on Characterising Liposome Formation
Malvern Panalytical has announced a new webinar ‘Characterising Liposome Formation, Structure and Stability with Complementary Techniques’ that will take place this month.
Comorbidities are a significant concern in people with Type 2 diabetes
Type 2 diabetes (T2D) is a chronic disorder of glucose equilibrium that results from the body’s inability to make use of available insulin along with relative insulin deficiency. Among adults only, T2D is expected to make up at least 95% of all diabetes cases.
Orthotopic and Metastasis Models for Preclinical Efficacy Testing of Novel Cancer Drugs
Lack of efficacy is one of the major causes of attrition in the clinical development of new compounds to treat cancer.
Stability Issues Related to Soft Gelatin Capsule Development
Stability issues are a challenge for formulators. The reactivity of formulations depends on many factors, although it is generally recognised that labile drugs in aqueous forms are sometimes the worst cases.
Gamlen Study: Breaking Anisotropic Rod-Shaped Particles
Gamlen presents a study conducted by V. Penkavova1, L. Kulaviak1, M.C. Ruzicka1, M. Puncochar, and P. Zamostny on the 'Beaking of Anisotropic Rod-Saped Particles'.
Through CRISPR gene editing we can change the nature of our species
In 2018, we can expect to see large numbers of CRISPR trials taking off all over the world and we should not be afraid of this technology, because we severely need it if we want to cure chronic disease or change our nature to better cope with a changing environment and new challenges for our species.
Amgen/UCB’s bone-forming agent, Evenity, accepted for review by EMA
On January 8, the European Medicine Agency (EMA) accepted Amgen and UCB’s submission for review for use of Evenity (romosozumab), a novel anabolic agent for the treatment of postmenopausal women and men with osteoporosis.
Can Liquidia’s LIQ861 offer a more convenient and effective treprostinil option for PAH patients?
On January 3, 2018, Liquidia Technologies announced the initiation of a Phase III clinical trial evaluating LIQ861 (inhaled treprostinil) for the treatment of pulmonary arterial hypertension (PAH).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.